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ABSTRACT 
 
Substantial evidence has shown that dopamine (DA), particularly in the nucleus accumbens 
(NAc), is involved in behavioral activation and effort-related processes, such as overcoming 
work related response costs. Behavioral paradigms have been developed to assess effort-related 
choice behavior in rodents, including maze procedures and operant tasks. Interference with 
accumbens DA transmission through administration of the vesicular monoamine transportor-2 
(VMAT-2) inhibitor tetrabenazine (TBZ) produces an alteration of response allocation in the 
concurrent FR5/chow choice procedure, biasing animals toward the lower effort alternative. The 
effects of TBZ are consistent with DA depletions and administration of DA D1 or D2  family 
antagonists. It has been suggested that these drug-induced shifts in effort-related choice behavior 
seen in rodents are analogous to symptoms such as psychomotor retardation, anergia, and fatigue, 
which can be observed in people with depression and other related disorders. Previous studies 
have shown the effects of TBZ on lever pressing and chow consumption can be attenuated 
through co-administration of the putative antidepressant MSX-3, an adenosine A2A antagonist, 
the monoamine-oxidase (MAO)-B inhibitor, deprenyl, as well as the well-known antidepressant 
bupropion. Recently, clinical studies have shown antidepressant efficacy of curcumin, a MAO-
A/B inhibitor, as an adjunct medication. Curcumin is a naturally occurring compound found in 
turmeric, a prominent ingredient of curry powder used in ethnic foods. Curcumin has proven 
successful in traditional rodent models of depression such as the tail suspension or forced swim 
test. The current study investigated the ability of curcumin to reverse the effects of TBZ on 
effort-related choice behavior. The effects of TBZ on lever pressing were partially reversed by 
ingestion of a high dose of curcumin two hours prior to testing. A major problem with curcumin 
is its poor bioavailability due to fast metabolism; therefore future studies should investigate ways 
to enhance the absorption of curcumin.  
1 - Introduction 
 
 To survive, organisms must overcome environmental obstacles that separate them from 
motivationally significant stimuli. In order to overcome constraints, organisms need to exert 
effort through effort-related decision-making revolving around cost/benefit analyses (Salamone 
& Correa, 2002). There are numerous variables that influence these choices, with one of the most 
important being interactions based upon work requirements and reinforcement value (Salamone 
& Correa, 2002; Salamone et al., 2003, 2005, 2007). Substantial evidence has indicated that the 
mesolimbic dopamine (DA) pathway, particularly DA within the nucleus accumbens (NAc), is 
involved in effort-related processes, such as overcoming work-related response costs in 
instrumental behavior (Barbano & Cador, 2007; Phillips et al., 2007; Salamone et al., 2005, 
2007). Interference with DA transmission can affect the relative allocation of behavior in animals 
responding on tasks that assess effort-based choice behavior; biasing animals towards the lower 
effort alternative (Floresco et al., 2008; Salamone et al., 2005, 2007).  
 Tests of effort-related choice behavior offer animals choices between a more highly 
valued reward that can be obtained by a high degree of effort vs. a low effort/low reward option.  
One procedure that is used to study the effects of dopaminergic manipulations on effort-related 
choice behavior is the concurrent FR5/chow feeding choice task. This operant choice task offers 
rats the option of lever pressing to obtain a more preferred food (BioServe high carbohydrate 
pellets), or approaching and consuming a concurrently available less preferred standard lab chow. 
Under baseline or control conditions, when the FR requirement is relatively low (i.e., FR1 or 
FR5), trained rats will receive most of their food from lever pressing and consume only a small 
quantity of the lab chow (Cousins et al., 1993; Nowend et al., 2001; Salamone et al., 1991, 1997). 
Interfering with DA neurotransmission through DA depletions and local or systemic 
administration of DA D1 or D2 family antagonists produce a reallocation of behavior, such that 
lever-pressing is significantly decreased and consumption of the lab chow is increased (Nunes et 
al., 2010; Salamone et al., 2002; Sink et al., 2008; Worden et al., 2009). A similar behavioral 
profile is produced after administration of the reversible vesicular monoamine transporter-2 
(VMAT-2) inhibitor tetrabenazine (TBZ). By inhibiting VMAT-2, TBZ blocks vesicular storage 
and depletes monoamines, with its greatest impact being upon striatal DA (Pettibone et al., 1984). 
Additionally, TBZ has been shown to affect DA signal transduction in a manner that is consistent 
with reduced ventral striatal DA D1 and D2 receptor neurotransmission (Nunes et al., 2013). The 
concurrent FR5/chow choice task has been extensively validated to demonstrate that the effects 
of interference of NAc DA transmission are not due to changes in appetite, food intake, or 
preference (Salamone et al., 1991), and do resemble effects of reinforced evaluation by 
prefeeding (Nunes et al., 2013; Salamone et al., 1991) or appetite suppressant drugs (Salamone et 
al., 2002; Sink et al., 2008).  
It has been suggested that tasks measuring effort-based decision-making could be useful 
to model the effort-related motivational symptoms such as fatigue, psychomotor slowing, and 
anergia seen in depression and other related disorders (Salamone & Correa, 2012).  It has been 
reported that these symptoms are among the most common in psychiatric medicine but are the 
most difficult to treat as they are resistant to antidepressant treatment (Fava et al., 2013; Stahl, 
2002). Therefore, these paradigms may be beneficial for developing adjunct medication to treat 
these motivational dysfunctions. Tests of effort-related decision-making have been developed in 
humans (Treadway et al., 2011), and have shown that individuals with major depressive disorder 
show reduced selection of higher effort alternatives (Treadway et al., 2012).  Reversal studies 
(e.g., co-administration of another compound) are used as pre-clinical assessment of potential 
treatments. Co-administration of the adenosine A2A antagonist, MSX-3, was able to attenuate the 
shifts in behavior induced by TBZ (Nunes et al., 2013). Additionally, the widely used 
antidepressant drug bupropion, a catecholamine uptake blocker, and L-deprenyl, a monoamine 
oxidase-B (MAO-B) inhibitor, attenuate the effort-related shifts induced by TBZ (Nunes et al., 
2013; Randall et al., submitted).  
Curcumin is a naturally occurring compound found in turmeric powder, that has been 
shown to possess action as an inhibitor of both MAO-A and MAO-B enzymes (Kulkarni et al., 
2005). By inhibiting the activity of monoamine oxidase, curcumin prevents the breakdown of 
monoamines and thereby increases their availability. Levels of both serotonin (5-HT) and DA 
were increased following administration of curcumin, and levels of norepinephrine (NE) were 
not altered (Kulkarni et al., 2008). There is a dose-dependent effect of curcumin on the MAO-B 
enzyme. Curcumin’s action on this enzyme is achieved at high doses as compared to inhibition 
of the MAO-A enzyme which is achieved a low doses (i.e., 5 mg/kg vs. 40 mg/kg; Kulkarni et al., 
2008). The antidepressant profile of curcumin has been explored in animal models of behavioral 
despair, which are employed as antidepressant screening paradigms. Co-administration of 
curcumin with DA depleting agents, such as reserpine, decreased immobility time (Kulkarni et 
al., 2008).  Moreover, curcumin further enhanced the anti-immobility effect of the nonselective 
MAO inhibitor, tranylcypromine, as well as selegiline, a MAO-B inhibitor, in the mouse forced 
swim test (Kulkarni et al., 2008). Together these studies confirm the MAO inhibiting activity of 
curcumin. Recently, curcumin has been shown to be effective in human-clinical trials as an 
adjunct medication for depression (Bergman et al., 2013).  
Previous studies that have investigated the antidepressant-like effects have administered 
curcumin orally via gavage feeding (Kulkarni et al., 2008; Xu et al., 2005). Gavage is the 
introduction of a solution into the stomach by means of inserting a small-diameter tube into the 
esophagus, and delivering the drug directly into the stomach by means of a syringe. Although 
highly effective, this method can cause esophageal injury as well as restraint-associated distress, 
particularly with repeated use (Brown et al., 2000). Stress induced alterations include changes in 
gastric secretion and mobility, changes in heart rate and increases in plasma glucocorticoids 
(Kent et al., 1986; Brown et al., 2000). Moreover, this stress-induced response can last up to one 
hour after (Bonnichsen et al., 2005). A prior study reported a 32% mortality rate attributed to 
granulomatous inflammation caused by gavaging that ultimately lead to asphyxia (Germann & 
Ockert, 1994).  
The aim of the current study is to investigate the effects of ingested curcumin pellets to 
attenuate TBZ induced shifts in behavior in rodents responding on the concurrent FR5/chow 
choice procedure. Self-administration of curcumin pellets by animals will reduce adverse effects 
and distress due to gavaging and thereby provides an alternative to gavage.  In addition, blood 
assays and tissue harvesting were conducted to determine rate of absorption and metabolism of 
curcumin.  
 
2. Materials and Methods 
2. 1 Animals 
 Adult male Sprague-Dawley rats (Harlan-Sprague Dawley, Indianapolis, IN, USA) were 
pair housed in a colony maintained at 23° C with 12-h light/dark cycles (lights on at 7:00h).  Rats 
(n=7) weighed approximately 300-350 grams at the beginning of the study, and were initially 
food restricted to 85% of their free-feeding body weight for operant training.  Rats were fed 
supplemental chow to maintain the food restriction throughout the study, with ad libitum water, 
and were allowed modest weight gain throughout experiments.  Animal protocols were approved 
by the University of Connecticut institutional animal care and use committee, and followed NIH 
guidelines. 
2.2 - Pharmacological Agents and Dose Selection  
Tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b 
hexahydrobenzo[a]quinolizin-2-one), the VMAT-2 inhibitor, was purchased from Tocris 
Bioscience (Bristol, UK). Tetrabenazine was dissolved in a vehicle solution of 0.9% saline 
(80%) and DMSO (20%). 1N HCl /mL volume was then added to adjust the pH and get the drug 
completely into solution. The final pH of the tetrabenazine solution was 3.5. The saline with 20% 
DMSO vehicle solution was administered as the vehicle control. The 0.75 mg/kg dose of 
tetrabenazine which was used for the FR5/chow choice task was based on extensive pilot work 
done in our laboratory.  All injections were administered intraperitoneal (IP).  
Curcumin pellets were formulated by grinding 28 mg of BioServe (Frenchtown, NJ, 
USA) and 7 mg of curcumin together, to give a total weight of 35 mg per pellet. Curcumin 
pellets were pressed fresh weekly and were stored in a desiccator. All pellets were made by the 
University of Connecticut, School of Pharmacy.  The dosages of curcumin were adjusted by 
pellet number. Animals needed to consume at least half of the pellets to be considered successful 
in achieving the desired dose.  
2.3 Behavioral Procedures 
Concurrent FR5/chow-choice procedure: Behavioral sessions were conducted in operant 
conditioning chambers (28x23x23 cm3, Med Associates, Georgia, VT, USA) during the light 
period. Rats (n = 9) were initially trained to lever press on a continuous reinforcement schedule 
(30 minute sessions, during 5 days/week) to obtain 45mg pellets, (Bioserve, Frenchtown, NJ, 
USA), and then were shifted to the FR5 schedule (30 minute sessions, 5 days/week) and trained 
for several additional weeks until reaching a predetermined baseline number of lever presses (i.e., 
consistent responding • 1,200 lever presses). Animals needed to consistently reach baseline 
criteria for the course of approximately one week before being introduced to the concurrent 
FR5/chow-feeding choice procedure. In this task, weighed amounts of laboratory chow 
(Laboratory Diet, 5P00 Prolab RHM 3000, Purina Mills, St. Louis, MO, USA; typically 20-25 
grams, four-five large pieces) were concurrently available in the chamber during the 30 min FR5 
session. Rats also received feeding study training and were trained to consume 10 Bioserve 
pellets on baseline days 2 hours prior to running. Before inclusion in the experiment, all animals 
were exposed to 10 (highest dose, 160 mg/kg) curcumin to insure consumption. Animals were 
trained on the procedure until approximately the entire dosage (i.e., 8/10 pellets) was consumed.   
On experimental testing days, when TBZ was administered, the rats were administered 80 mg/kg 
and 160 mg/kg of the curcumin pellet formulation 2 hours prior to running. At the end of the 
FR5/chow choice session, rats were immediately removed from the chambers, lever pressing 
totals were recorded, and amount of chow consumed was determined by weighing the remaining 
food and spillage. Rats were trained until reaching and maintaining stable levels of baseline lever 
pressing and chow intake. Once animals achieved baseline rates experimental testing began. 
2.4 Experimental Procedures 
 Animals received a vehicle injection one week prior to beginning testing in order to 
habituate them to being injected.  Additionally, animals received curcumin pellets one week 
prior to testing in order to assure accurate consumption. All experiments used a within-group 
design in which each rat received all drug or vehicle treatments in the experiment in a randomly 
varied order (one treatment per week). Baseline training sessions (i.e., non-drug) were conducted 
4 days per week.  
2.4.1 Experiment 1: Ability of MAO-inhibitor curcumin to reverse the effects of TBZ.  
Rats were trained before drug testing as described above. Rats (n=7) were given 15 minutes to 
consume pellets administered 2 hours prior to testing. Animals received the following 
treatments; vehicle plus 10 Bioserve pellets (VEH/BIO), tetrabenazine plus 10 Bioserve pellets 
(TBZ/BIO), tetrabenazine plus 80 mg/kg curcumin (TBZ/80), and tetrabenazine plus 160 mg/kg 
curcumin (TBZ/160). Animals who were over 400 grams, received one extra pellet. Remnants of 
the pellets were collected and weighed to determine the total dose of curcumin administered. 
Next, rats received an injection of either 0.75 mg/kg TBZ or vehicle 90 minutes prior to testing.  
2.4.2 Experiment 2: Assays of tissue levels of curcumin to determine rate of absorption  
Rats were randomly assigned to consume either 80 or 160 mg/kg curcumin 2 hours prior to live 
decapitations. Animals were placed into CO2 for approximately 2 minutes and were quickly 
removed. Cardiac punctures were performed to acquire at least 5 cc’s of blood. Afterwards, the 
liver, brain, and small intestine were removed for analysis.  
2.5 Data Analysis 
In experiment 1, total number of lever presses and gram quantity of chow intake from the 30 min 
session were analyzed using repeated measures ANOVA. A computerized statistical program 
(SPSS 21.0 for Windows) was used to perform all analyses. When there was a significant 
ANOVA, non-orthogonal planned comparisons using the overall error term were used to assess 
the differences between each treatment and the control condition. The number of comparisons 
was restricted to the number of treatments minus one (Keppel, 1991). For the effect size 
calculations partial eta-squared was used (η ρ ²). In experiment 2, a bivariate correlation was run 
between dose of curcumin administered and curcumin tissue concentration. Pearson’s correlation 
coefficient (r) was used to determine the linear dependence between the two variables.  
3. Results   
Experiment 1: Ability of curcumin to reverse the effects of TBZ. 
 The MAO A/B inhibitor, curcumin, produced a partial reversal of the effects of TBZ in 
animals tested on the FR5/chow feeding choice test (Figure 1). Repeated measures ANOVA 
showed that there was an overall significant effect of drug treatment on lever pressing 
[F(3,18)=10.17, p<0.001]. Planned comparisons revealed that TBZ produced a significant 
reduction in lever pressing compared to vehicle control conditions (p<0.05). Co-administration 
of 160 mg/kg curcumin with TBZ significantly increased lever pressing compared to TBZ plus 
vehicle (planned comparisons, p<0.05). The drug treatment effect was marked by a moderately 
high effect size (η 2 = 0.629).  The overall treatment effect for chow consumption was also 
statistically significant [F(3,18)=12.121, p<0.001].  Chow intake was significantly increased by 
TBZ relative to the vehicle-vehicle condition (planned comparisons, p<0.05). Chow intake was 
significantly reduced at the 160 mg/kg dose of curcumin (planned comparisons, p<0.05). The 
effect size of drug treatment on chow consumption was moderately high (η 2 = 0.669). Thus, co-
administration of curcumin (160 mg/kg) with TBZ significantly increase lever pressing and 
decreased chow consumption compared to TBZ-vehicle treated animals.   
Experiment 2: Assays of tissue levels of curcumin to determine rate of absorption  
 The bioavailability of curcumin despite the dose administered produced similar blood 
serum concentrations (Figure 2). A bivariate correlation between dose consumed and 
concentration revealed that 80 and 160 mg/kg produced nearly identical levels. There was a very 
strong correlation for both 80 mg/kg (r=0.918) and 160 mg/kg (r=0.907). 
4. Discussion 
 
 TBZ is currently used to treat Huntington’s disease, and is known to produce depressive 
side effects, including motivational symptoms, in some patients (Frank et al., 2009; 2010). By 
inhibiting VMAT-2, TBZ affects monoamine storage, but studies indicate that the greatest 
effects are on striatal DA (Pettibone et al., 1984; Nunes et al., 2013). Similar to the effects 
produced by interfering with NAc DA, TBZ produced a shift in choice behavior in rats 
responding on the concurrent FR5/chow choice task. Compared to control animals, TBZ-treated 
animals have decreased lever pressing and increased consumption of the lab chow. Animals 
administered TBZ expend minimal effort when an alterative food source is available at lower 
cost (i.e., the freely available chow). Although TBZ-treated rats show significant reductions in 
food-reinforced lever pressing, they remained directed towards the acquisition and consumption 
of food. Similar to the effects produced by administration of DA D1 or D2 family antagonists, the 
effects induced by TBZ substantially differed from pre-feeding to reduce food motivation 
(Salamone et al., 1991), and appetite suppressant drugs such as amphetamine (Cousins et al., 
1994) and CB1 antagonists and inverse agonists (Sink et al., 2008), all of which failed to increase 
chow consumption at doses that suppressed lever pressing.  
 The TBZ induced shifts in behavior can be attenuated by co-administration of the 
adenosine A2A antagonist, MSX-3, the catecholamine uptake inhibitor bupropion, and the MAO-
B inhibitor deprenyl (Nunes et al., 2013; Randall et al., submitted). The present study 
investigated the MAO-A and B inhibitor, curcumin, to reverse the behavioral effects of TBZ. 
Co-administration of 160mg/kg curcumin two hours prior testing can successfully attenuate TBZ 
induced effects.  Previously, curcumin has been shown to produce antidepressant-like effects in 
rodent tasks such as the forced swim test (Xu et al., 2005) and the tail suspension task (Xu et al., 
2005). Curcumin produces effects in these paradigms that are comparable to well-known 
antidepressants such as fluoxetine, desipramine, and imipramine (Lucki, 1997). The ability of 
curcumin to attenuate the shift in behavior is similar to the MAO-B inhibitor l-deprenyl (Randall 
et al., submitted). Moreover, in antidepressant screening paradigms curcumin has been combined 
with subthreshold doses of antidepressants, and has further attenuated immobility time 
(Sanmukhani et al., 2011). In addition, a recent human clinical trial has paired curcumin as an 
adjunct medication to treatment with fluoxetine (Prozac) for depression (Sanmukhani et al., 
2013). Patients with add-on curcumin plus fluoxetine had a better ranking on the Hamilton 
Depression Rating Scale compared to those without curcumin (Sanmukhani et al., 2013). Taken 
together, these studies suggest that curcumin could further potentiate current antidepressants. 
Previous studies have administered the dopamine norepinephrine reuptake inhibitor, bupropion, 
with TBZ in operant task (Nunes et al., 2013; Randall et al., submitted) and maze paradigms 
(Yohn et al., submitted). Bupropion, like l-deprenyl and curcumin, also produced a partial 
reversal of TBZ induced deficits in choice behavior (Nunes et al., 2013; Randall et al., 
submitted; Yohn et al., submitted). Future studies should investigate the ability of subthreshold 
doses of bupropion plus curcumin to attenuate effort-related shifts in behavior caused by TBZ.   
 Various animal models (Shankar et al., 1980) or human clinical studies (Lao et al., 2006) 
have proved that curcumin is extremely safe even at high doses.  The pharmacological safety of 
curcumin makes it a potential compound for the treatment of depression, however, a major issue 
with curcumin is that is has very poor bioavailability. Curcumin has low intrinsic activity, high 
rate metabolism and poor absorption (Anand et al., 2007). Previous studies have indicated that 
the route of administration plays a role in achievable serum levels and tissue distribution (Anand 
et al., 2007). For instance a study conducted by Ravindranath & Chandrasekhara (1981) revealed 
less than 3% of curcumin was found in the liver, small intestine, and stomach tissues at the 
highest dose of curcumin. Moreover, the percentage of curcumin absorbed remained constant 
regardless of dose, indicating that administration of more curcumin does not result in higher 
absorption (Ravindranath & Chandrasekhara, 1981). Similarly, the blood serum results from the 
current study are consistent with the literature. The concentration of curcumin in blood serum is 
independent of dosage. For example, both the 80 and 160 mg/kg dose of curcumin displayed 
roughly the same total concentration of curcumin. Additionally, previous studies have shown that 
curcumin has extremely low serum levels (Anand et al., 2007). Similar to rodents, oral 
administration of 2 grams curcumin daily in humans produced undetectable serum levels (Cheng 
et al., 2001). Together, these studies with the current results suggest there is a dose-dependent 
limitation to bioavailability. The addition of an excipient to curcumin has been shown to improve 
the bioavailability (Anand et al., 2007; Kulkarni et al., 2008; Shoba et al., 1998). Therefore, 
future studies should investigate the potential of curcumin paired with an adjuvant.  
 Neusilin has been proposed as a possible bioavailability enhancer that may be paired with 
curcumin (Williams et al., 2014; Yan et al., 2011). Using curcumin prepared with phytosomes 
has also been shown to improve the uptake into the blood (Marczylo et al., 2007), and that the 
peak of curcumin in blood is 15 minutes after oral gavage administration.  Other studies have 
used piperine, another natural compound found primarily in hot jalapeno peppers, to increase the 
bioavailability of oral curcumin dosing by 154% (Kulkarni et al., 2008; Shoba et al., 1998).  
Piperine’s combined effects with curcumin have also been studied examining the anti-depressant 
like effect on chronic-stress induced behavior (Bhutani et al., 2009). Prior studies have 
demonstrated that piperine enhances the oral bioavailability of curcumin in both rats and humans 
at doses that were devoid of adverse side effects (Shoba et al., 1997). Piperine has been shown to 
inhibit the metabolism of curcumin and enhance its bioavailability.   
 Additionally, during collection it was noted that, majority of the curcumin pellets were 
still located within the stomach and small intestine. Taking this into consideration, future studies 
should extend the lead-time of curcumin. Prior studies have found that curcumin remains active 
in the system 90 minutes to three hours after administration (Anand et al., 2007). Moreover, 
previous studies have used IP or oral injections of curcumin, which have faster absorption rates 
(Pan et al., 1999). Prior studies have shown that negligible amounts of curcumin have been found 
in blood plasma of rats after oral administration of 1 g/kg of curcumin indicating that curcumin 
was poorly absorbed from the gut (Wahlstrom & Blennow, 1978). Since very little curcumin is 
absorbed from the gut and small intestine, future studies should investigate rate of absorption of 
curcumin with an excipient. 
  As mentioned before, curcumin has already been employed in studies testing its effects 
as an enhancer of antidepressant medication (Kulkarni et al., 2008; Sanmukhani et al., 2013).  
With the results from this study, we provide further evidence that it can be used for depression, 
schizophrenia, and other related disorders that have motivational symptoms.  People with 
neurological disorders, especially those related to inflammation, may consider using curcumin as 
a natural herbal remedy, by suggesting a change of diet involving an increased intake of curry 
foods.  This adds to the growing field of complementary and alternative medicine, and may be 
able to help those who cannot take the normally prescribed medications due to either medical or 
personal reasons. 
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Figure 1: The effects of the MAO-A/B inhibitor curcumin on TBZ-induced changes in rats 
performing on the concurrent FR5/chow choice task. Rats received IP injections of vehicle or 
0.75 mg/kg 90 minutes prior to testing. In addition, rats were administered curcumin two hours 
prior to testing. (A) Mean (±SEM) number of lever presses (FR5 schedule) during the 30 minute 
session. (B) Mean (±SEM) gram quantity of chow intake. TBZ significantly decreased lever 
pressing and increased chow consumption relative to vehicle (# p<0.05). Administration of 160 
curcumin to TBZ-treated rats 2 hours prior to testing significantly increased lever pressing and 
decreased chow consumption relative to treatment with TBZ alone (* p<0.05). 
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Figure 2: Blood serum concentrations of curcumin to assess rate of absorption. Rats received 
either 80 or 160 mg/kg curcumin two hours prior to collection. (A) Linear trend with a strong 
positive correlation of the amount of curcumin consumed and serum levels in the 80 mg/kg dose 
(r=0.918). (B) Positive correlation of the effects of 160 mg/kg curcumin on amount detectable in 
blood serum (r=0.907). Despite the dose and amount consumed, both doses have similar serum 
concentration levels.  
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